TICKERNERD
Menu
CVSAConsumer Defensive · Education & Training Services

CVSA Stock Forecast: Covista, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026
$125
−1.26% on the day

The 4 Wall Street analysts covering Covista, Inc. hold a median 12-month price target of $155 — +24.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$4.2B
Ticker Nerd rank
90 / 100
Median analyst target
$155
Analysts covering
4
Total return, dividends reinvested
1W
+7.8%
1M
−2.6%
YTD
+20.7%
1Y
+9.3%
From 52W high
−19.2%
From 52W low
+39.7%
$89
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Covista, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Revisions
84
Quality
80
Accruals
72
Value
70
Volatility
64
Momentum
56
Growth
48
Size
26

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (48): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Covista, Inc. — and when they’d sell — is the membership.

Wall Street

CVSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160$180Oct 25Jan 26Apr 26Jul 26CVSAHigh $175Median $155Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $140Median $155High $175

The green dot is the last close — the median target sits +24.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 June 2026Barrington ResearchMaintainsOutperform$170
11 May 2026Truist SecuritiesMaintainsBuy—
17 Apr 2026Barrington ResearchMaintainsOutperform—
24 Mar 2026Truist SecuritiesInitiatesBuy—
2 Mar 2026Barrington ResearchMaintainsOutperform—
29 Jan 2026Barrington ResearchMaintainsOutperform—
31 Oct 2025Barrington ResearchMaintainsOutperform—
15 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
8 Aug 2025Barrington ResearchMaintainsOutperform$140 → $150
30 July 2025Barrington ResearchMaintainsOutperform$140
12 May 2025BMO CapitalMaintainsOutperform$115 → $132
9 May 2025Barrington ResearchMaintainsOutperform$120 → $140
23 Apr 2025JefferiesInitiatesBuy$135
15 Apr 2025Barrington ResearchMaintainsOutperform$120
3 Feb 2025BMO CapitalMaintainsOutperform$108 → $115
31 Jan 2025Barrington ResearchMaintainsOutperform$115 → $120
17 Jan 2025Barrington ResearchMaintainsOutperform$95 → $115
30 Oct 2024Barrington ResearchMaintainsOutperform$90 → $95
30 Oct 2024BMO CapitalMaintainsOutperform$84 → $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CVSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Covista, Inc. (CVSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.2×

Cheaper than 42% of US stocks

Price / sales
2.2×

Cheaper than 50% of US stocks

Price / book
3.1×

Cheaper than 33% of US stocks

EV / EBITDA
11.4×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
4.5%

Higher than 40% of US stocks

Earnings growth (YoY)
−31.6%

Higher than 15% of US stocks

Gross margin
56.7%

Higher than 71% of US stocks

Operating margin
18.9%

Higher than 79% of US stocks

Net margin
12.3%

Higher than 74% of US stocks

Returns & dividend
Return on equity
17.9%

Higher than 79% of US stocks

Return on assets
8.4%

Higher than 89% of US stocks

Dividend yield
0.3%

Higher than 5% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CVSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelEducation & Training Services
CompanyMarket capTKN rank
CVSACovista, Inc.$4.2B
90
LOPEGrand Canyon Education, Inc.$3.9B
73
LRNStride, Inc.$3.5B
77
LAURLaureate Education, Inc.$5.4B
84
XXITwenty One Capital, Inc.$2.8B
0
UTIUniversal Technical Institute, Inc.$2.1B
36
MHMcGraw Hill, Inc.$2.1B
27
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CVSA news & analysis

Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors

Business Wire · 28 July 2026positive

Covista announced the appointments of Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026. The additions come as the company launches its three-year growth strategy called Purpose at Scale.

Why it matters — New board members with deep experience in technology, fintech and edtech could provide valuable guidance as Covista executes its strategy to address healthcare workforce challenges.

FAQ

Frequently asked questions about CVSA stock

What is the CVSA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Covista, Inc. have a median 12-month price target of $155, with estimates ranging from $140 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVSA stock a buy right now?

Of the 4 analysts covering Covista, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Covista, Inc. 90 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVSA?

As at 1 Aug 2026, Covista, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will CVSA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +24.1% from the last close, and Ticker Nerd's factor model ranks Covista, Inc. 90 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVSA stock forecast for 2030?

No analyst covering Covista, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $175 over the next 12 months.

How has CVSA stock performed over the past year?

Covista, Inc. returned +9.3% over the 12 months to 31 July 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Covista, Inc. do?

Adtalem Global Education Inc. is a premier educational services company focused on empowering students to achieve their academic and career goals.

What is the latest news on CVSA?

The most recent item we track (Business Wire, 28 July 2026): "Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors". Covista announced the appointments of Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026. The additions come as the company launches its three-year growth strategy called Purpose at Scale.

Company

About Covista, Inc.

Adtalem Global Education Inc. is a premier educational services company focused on empowering students to achieve their academic and career goals. Specializing in providing undergraduate, graduate, and professional degrees, Adtalem operates through a network of institutions and is involved in various sectors, including healthcare, business management, and legal education. The organization is committed to increasing access to educational opportunities, equipping students with the skills necessary for a global workforce. Noteworthy institutions under the Adtalem umbrella include the Chamberlain University, known for its nursing programs, and the Ross University School of Medicine, supporting medical education. Through these entities, Adtalem not only addresses the significant demand for skilled professionals but also contributes to societal needs with its healthcare and business-oriented programs. Adtalem plays a critical role in the financial market by catering to an ever-present need for professional education, aligning with industry requirements and workforce development trends. As the demand for qualified professionals continues to rise, Adtalem's strategic positioning in the education sector underscores its importance and resilience in the market.

CEO Mr. Stephen W. Beard J.D. · 4,703 employees · United States · https://www.covista.com